What analyst predict for Vertex Pharmaceuticals Incorporated NASDAQ:VRTX
Vertex Pharmaceuticals Incorporated NASDAQ:VRTX
Vertex Pharmaceuticals Incorporated is stock market daily expected to report earnings on 04/26/2018 after market close. The report will be for the fiscal Quarter ending Mar 2018. According to Zacks Investment Research, based on 7 analysts forecasts the consensus EPS forecast for the quarter is $0.26. The reported EPS for the same quarter last year was $0.13.
Overview of Vertex Pharmaceuticals Incorporated NASDAQ:VRTX
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.
We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ 2,100 people in the United States, Europe, Canada and Australia with nearly two-thirds of our staff dedicated to research and development.
Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.
|% Change from 52 Week Low|
|% Change from 52 Week High|